Standard Lipid Panel: When to Order This Test

What a Standard Lipid Panel Actually Measures

A standard lipid panel quantifies four circulating lipid fractions from a single blood draw: total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. Most laboratories also calculate very-low-density lipoprotein cholesterol (VLDL-C) and non-HDL cholesterol (total cholesterol minus HDL-C) from these values. LDL-C is typically estimated using the Friedewald equation rather than measured directly, though this formula becomes unreliable when triglycerides exceed 400 mg/dL [1].

Non-HDL-C has gained clinical traction because it captures all atherogenic particles, including VLDL remnants and lipoprotein(a). The 2018 AHA/ACC cholesterol guideline identifies non-HDL-C as a secondary target after LDL-C, particularly in patients with elevated triglycerides or metabolic syndrome [2]. A single lipid panel therefore provides more clinical signal than most patients or clinicians realize.

Who Should Be Screened and When

The USPSTF recommends lipid screening for all adults aged 40 to 75 who have one or more cardiovascular risk factors, including dyslipidemia itself, diabetes, hypertension, or smoking [3]. This is a B-grade recommendation, meaning the net benefit is moderate to substantial. For adults without traditional risk factors, screening remains reasonable starting at age 20 per ACC/AHA guidance, repeated every 4 to 6 years if the initial panel is normal [2].

Children and adolescents warrant screening too. The National Heart, Lung, and Blood Institute recommends universal screening at ages 9 to 11 and again at 17 to 21 [4]. Earlier screening is appropriate when a first-degree relative had a myocardial infarction or stroke before age 55 (men) or 65 (women), which may signal familial hypercholesterolemia affecting roughly 1 in 250 individuals [5].

Order the test sooner than the routine interval when a patient starts statin therapy, begins a GLP-1 receptor agonist, or undergoes bariatric surgery. Post-intervention panels at 4 to 12 weeks confirm response.

Normal Ranges and What the Numbers Mean

Lipid panel reference ranges follow the ATP III classification framework updated by subsequent AHA/ACC guidelines [6]. Here is how to interpret each component:

Total cholesterol: Desirable is below 200 mg/dL. Borderline high runs 200 to 239 mg/dL. Levels at or above 240 mg/dL are classified as high.

LDL-C: Below 100 mg/dL is optimal for the general population. For patients with established atherosclerotic cardiovascular disease (ASCVD), LDL-C below 70 mg/dL is the treatment target. Some guidelines now support below 55 mg/dL for very high-risk patients. The 2019 ESC/EAS dyslipidemia guideline states, "For patients at very high cardiovascular risk, an LDL-C reduction of ≥50% from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) are recommended" [7].

HDL-C: Levels below 40 mg/dL in men or below 50 mg/dL in women are considered low and independently increase cardiovascular risk. Very high HDL-C (above 80 to 100 mg/dL) does not appear to be additionally protective and may reflect dysfunctional HDL particles in some cases [8].

Triglycerides: Normal is below 150 mg/dL fasting. Borderline high is 150 to 199 mg/dL. Values above 500 mg/dL carry risk for acute pancreatitis and require urgent management independent of cardiovascular considerations.

Fasting vs. Non-Fasting: Which to Order

For decades, a 9- to 12-hour fast was considered mandatory before a lipid panel. That requirement has softened. A 2016 joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry concluded that non-fasting lipid profiles are sufficient for routine screening [9]. Total cholesterol, HDL-C, and LDL-C change minimally after meals. Triglycerides are the exception, rising 20 to 30 mg/dL postprandially.

The practical implication: order a non-fasting panel for initial screening or cardiovascular risk assessment. Reserve fasting panels for patients with known hypertriglyceridemia, those being monitored on triglyceride-lowering therapy (fibrates, icosapent ethyl, high-dose omega-3), or when the calculated LDL-C appears unreliable. The 2018 AHA/ACC guideline explicitly endorses non-fasting samples for initial screening, noting that "a fasting lipid profile is preferred when a baseline triglyceride level is also needed" [2].

How Often to Repeat the Panel

Screening frequency depends on baseline risk, treatment status, and whether the initial panel showed abnormalities. The AHA recommends every 4 to 6 years for low-risk adults aged 20 and older with normal results [2]. Annual testing is appropriate for patients with diabetes, metabolic syndrome, or borderline values. The American Diabetes Association's Standards of Care 2024 recommends a lipid panel at diabetes diagnosis, at initial medical evaluation, and at least annually thereafter [10].

After starting or adjusting statin therapy, check a follow-up panel in 4 to 12 weeks to assess LDL-C response. A 30 to 50% reduction from baseline is expected with moderate- to high-intensity statins [2]. If the LDL-C target is not reached, guidelines recommend intensification (switching to high-intensity statin, adding ezetimibe, or considering a PCSK9 inhibitor) with repeat labs 4 to 12 weeks after each change.

For patients on stable, effective therapy with LDL-C at goal, annual panels are sufficient. Some payers require a lipid panel within 12 months to authorize refills of PCSK9 inhibitors like evolocumab or alirocumab.

Conditions That Should Trigger Immediate Testing

Do not wait for the next routine screen in these scenarios. Order a lipid panel now.

New diabetes diagnosis. At least 50% of adults with type 2 diabetes have dyslipidemia at diagnosis. The UKPDS demonstrated that each 1 mmol/L increase in LDL-C raised coronary heart disease risk by 57% in newly diagnosed type 2 diabetes patients [11].

Acute coronary syndrome. Lipids drawn within 24 hours of hospital admission reflect pre-event levels. Levels measured later may be falsely low due to the acute-phase response. The 2018 AHA/ACC guideline advises using admission lipid values to guide inpatient statin initiation [2].

Starting medications that alter lipids. Thiazide diuretics, beta-blockers, oral contraceptives, retinoids, protease inhibitors, and corticosteroids can all shift lipid values. Baseline and follow-up panels are appropriate.

GLP-1 agonist or bariatric surgery. Semaglutide 2.4 mg reduced LDL-C by 3.1% and triglycerides by 12.4% in STEP 1 (N=1,961) at 68 weeks [12]. Bariatric surgery often produces more dramatic improvements, with Roux-en-Y gastric bypass normalizing triglycerides in up to 80% of patients within 12 months. Pre- and post-treatment panels quantify benefit.

Family history of premature ASCVD or suspected familial hypercholesterolemia. LDL-C above 190 mg/dL in an adult without secondary causes strongly suggests heterozygous familial hypercholesterolemia. The Dutch Lipid Clinic Network criteria use LDL-C thresholds along with family and clinical history to establish the diagnosis [13].

Beyond the Basic Panel: When to Order Advanced Testing

A standard lipid panel is sufficient for most screening purposes. Consider advanced lipid testing when the standard panel does not fully explain the clinical picture. Dr. Seth Martin of Johns Hopkins has noted, "Non-HDL cholesterol and apolipoprotein B are better markers of atherogenic particle burden than LDL-C alone, particularly in patients with metabolic syndrome or diabetes" [14].

Apolipoprotein B (apoB): Measures the total number of atherogenic lipoprotein particles. The 2019 ESC/EAS guideline recommends apoB as a secondary treatment target, with goals of <65 mg/dL for very high-risk patients [7].

Lipoprotein(a) [Lp(a)]: Genetically determined and not affected by lifestyle. The 2022 Canadian Cardiovascular Society guideline recommends measuring Lp(a) at least once in every adult's lifetime to identify the approximately 20% of the population with elevated levels (>50 nmol/L or >30 mg/dL) [15]. Elevated Lp(a) independently increases ASCVD risk by 1.5- to 2-fold.

LDL particle number (LDL-P) or NMR lipoprofile: Useful when LDL-C and cardiovascular risk appear discordant, such as when LDL-C is at goal but the patient has metabolic syndrome and small, dense LDL particles.

Order these advanced tests selectively. For most patients, a standard lipid panel combined with a 10-year ASCVD risk calculator (Pooled Cohort Equations) provides adequate risk stratification.

How to Improve Lipid Panel Results

Lifestyle modifications remain first-line therapy for borderline values. A meta-analysis of 27 trials found that reducing dietary saturated fat intake lowered LDL-C by 10 to 15% on average [16]. Adding 5 to 10 grams daily of soluble fiber (oat beta-glucan, psyllium) produces an additional 3 to 5% LDL-C reduction. The PREDIMED trial (N=7,447) demonstrated that a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced major cardiovascular events by approximately 30% over 4.8 years, with associated improvements in HDL-C and triglycerides [17].

Aerobic exercise raises HDL-C by 3 to 6% and lowers triglycerides by 10 to 20% at moderate intensity (150 minutes per week). Weight loss of 5 to 10% body weight consistently improves all lipid fractions.

When lifestyle alone is not sufficient, the 2018 AHA/ACC guideline organizes pharmacotherapy by risk category. High-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) is the foundation for patients with clinical ASCVD, LDL-C ≥190 mg/dL, or diabetes aged 40 to 75 with LDL-C ≥70 mg/dL [2]. In the IMPROVE-IT trial (N=18,144), adding ezetimibe to simvastatin reduced LDL-C to a median of 53.7 mg/dL and further decreased cardiovascular events by 6.4% over 7 years compared to statin alone [18].

For severe hypertriglyceridemia (≥500 mg/dL), fibrates remain first-line to prevent pancreatitis. Icosapent ethyl (Vascepa) reduced cardiovascular events by 25% in the REDUCE-IT trial (N=8,179) among statin-treated patients with triglycerides 135 to 499 mg/dL [19].

Lipid Panels in Special Populations

Pregnant patients: Cholesterol and triglycerides physiologically increase 25 to 50% during pregnancy. Routine lipid screening during pregnancy is not recommended unless the patient had pre-existing dyslipidemia. Statins are contraindicated during pregnancy (FDA Category X). The AACE 2020 guideline recommends stopping statin therapy at least 4 to 6 weeks before conception [20].

Older adults (over 75): Evidence for initiating statin therapy in primary prevention weakens after age 75. The USPSTF found insufficient evidence to recommend screening in this group [3]. For older adults already on statins with good tolerance, continuation is reasonable based on ASCVD risk discussion.

Patients on testosterone replacement therapy (TRT): Exogenous testosterone may lower HDL-C by 5 to 15% while modestly reducing total cholesterol and LDL-C. The Endocrine Society guideline recommends a lipid panel at baseline and 6 to 12 months after starting TRT [21]. Monitoring becomes especially relevant in patients with baseline cardiovascular risk.

Patients on hormone replacement therapy (HRT): Oral estrogen raises HDL-C and triglycerides while lowering LDL-C. Transdermal estrogen has a more neutral triglyceride effect. Baseline and 3- to 6-month follow-up lipid panels help guide route-of-administration decisions, particularly in women with pre-existing hypertriglyceridemia.

Patients starting icosapent ethyl, bempedoic acid, or inclisiran should have panels drawn at 4 to 12 weeks post-initiation to confirm adequate response, with the interval matching the drug's time to steady-state LDL-C lowering.